MORETTI, ERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.195
EU - Europa 418
AS - Asia 136
AF - Africa 12
Totale 1.761
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.190
RU - Federazione Russa 248
IE - Irlanda 71
CN - Cina 59
SG - Singapore 49
IT - Italia 35
SE - Svezia 28
FI - Finlandia 20
HK - Hong Kong 18
CI - Costa d'Avorio 12
IN - India 7
GB - Regno Unito 6
CA - Canada 5
DE - Germania 5
JO - Giordania 3
UA - Ucraina 2
CZ - Repubblica Ceca 1
MK - Macedonia 1
NL - Olanda 1
Totale 1.761
Salva come PNG Salva come JPEG
Città #
Santa Clara 373
Fairfield 130
Cambridge 74
Ashburn 71
Dublin 71
Seattle 69
Woodbridge 67
Beijing 52
Houston 51
Chandler 46
Wilmington 45
Singapore 43
Princeton 21
Boston 20
Ann Arbor 14
Abidjan 12
San Diego 11
Florence 9
Altamura 8
Boardman 8
Lawrence 8
Moscow 7
Norwalk 6
Hillsboro 5
Medford 5
Mumbai 5
Toronto 5
Andover 4
New York 4
Shanghai 4
Yubileyny 4
Bremen 3
London 3
San Marzano sul Sarno 3
Hong Kong 2
Los Angeles 2
Lucera 2
Pune 2
Anguillara Sabazia 1
Busto Arsizio 1
Clifton 1
Dearborn 1
Falls Church 1
Grevenbroich 1
Jinan 1
Loucany 1
Munich 1
Pignone 1
Skopje 1
Totale 1.280
Salva come PNG Salva come JPEG
Nome #
Targeting triple negative breast cancer: is p53 the answer? 113
Adjuvant chemotherapy: which patient? What regimen? 107
The continued evidence from overviews: What is the clinical utility? 103
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. 99
Targeting triple negative breast cancer: is p53 the answer? 96
Re-searching anthracycline therapy 93
Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents 91
Taxanes in the elderly: Can we gain as much and be less toxic? 91
Predictive molecular markers of anthracycline effectiveness in early breast cancer 90
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. 87
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer 85
Predicting anthracycline benefit: have we made any progress? 84
Adjuvant systemic treatment for individual patients with triple negative breast cancer 83
Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream 82
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy 71
Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patients 64
Patients with triple negative breast cancer. 62
The role of topoisomerase II alpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients 57
Can we use anthracyclines as targeted agents?. 57
Triple negative breast cancer: a heterogeneous subgroup defined by what it is not 52
Topoisomerase 2 alpha (TOP2A) protein by automated quantitative analysis (AQUA) as a marker predicting sensitivity to single-agent epirubicin (E) in the neoadjuvant treatment of endocrine-resistant breast cancer (H-BC) 52
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial 45
Totale 1.764
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.542
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.542
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020234 0 0 0 0 34 37 33 33 32 26 32 7
2020/202188 7 11 3 2 7 10 2 10 12 9 11 4
2021/2022108 9 10 0 9 4 7 4 7 7 4 1 46
2022/2023227 38 16 3 12 22 43 40 14 19 4 15 1
2023/202497 3 14 24 6 5 12 8 11 4 4 3 3
2024/2025754 32 111 68 121 422 0 0 0 0 0 0 0
Totale 1.764